Introduction
Chronic wounds still represent a major clinical problem worldwide with significant morbidity and no effective therapy available. The healing response of wounded tissue is a complex process, involving the interplay of different cell types at the lesion site, including inflammatory cells, fibroblasts, keratinocytes, and endothelial cells. All these cell types mediate their functions by the release of a variety of soluble factors controlling, in a cell type-specific manner, cellular activation and proliferation in the wound space, remodeling of extracellular matrix and collagen deposition in the injured area, and new blood vessel formation in the granulation tissue (for recent reviews, see Ref. 1) . Among these factors are plateletderived growth factor (PDGF), 2 transforming growth factor-␤ (TFG-␤), 3 basic fibroblast growth factor (bFGF), 4 epidermal growth factor (EGF), 5 and nerve growth factor (NGF), 6 to name but a few. For wound healing, the induction of controlled neoangiogenesis at the lesion site is a fundamental process.
Healing is concomitant with an increase of production of and persistent over time. Delivery of VEGF165 to full thickness excisional wounds in rats resulted in remarkable induction of new vessel formation, with consequent reduction of the healing time. Histological examination of treated wounds revealed accelerated remodeling of epidermis and dermis, with formation of a thick granular layer, containing numerous newly formed capillaries, as well as vessels of larger size. These data underline the importance of neo-angiogenesis in the healing process and indicate that VEGF gene transfer might represent a novel approach to treat wound healing disorders.
Gene Therapy (2002) 9, 777-785. DOI: 10.1038/sj/gt/3301697 angiogenic growth factors from macrophages and keratinocytes and its impairment leads to a delay in skin repair. [7] [8] [9] [10] [11] One of the essential growth factors which are involved in the angiogenetic process in the wounded tissues is vascular endothelial growth factor (VEGF), 12 which promotes proliferation and migration of endothelial cells resulting in the formation of a capillary network which is an essential requisite for the healing process.
A consequence of the complexity of wound healing is the variety of conditions that can impair it, such as bacterial infection, malnutrition, underlying internal diseases and different therapeutic interventions. 13 The molecular basis of chronic non-healing wounds is unclear. One hypothesis which might be put forward is that growth factor activity is deficient in the wound environment. Growth factors might be trapped within extracellular matrix molecules, 14 or degraded by increased protease activity found in chronic non-healing wounds. 15 Alternatively, growth factor production might be impaired at the gene expression level, as we have recently observed for VEGF in the genetically diabetic mouse. 16 Given these considerations, it stems evident that a reasonable approach to alter the microenvironment of the wounded tissue and to stimulate wound healing is the topical application of growth factors. Although the results in animal studies are encouraging in this respect, 17 topical treatment with growth factors in the clinical setting is limited by several factors, such as their short half-lives, their inactivation by wound proteases, their poor bioavailability from the utilized vehicles, and the consequent need for daily applications and high initial doses that might result in toxicity. Thus, preliminary clinical trials have not produced the expected results. 18, 19 An alternative approach that might overcome most of these problems is the topical delivery of growth factorencoding genes into the relevant cells in the wound microenvironment. In this respect, the easy accessibility of the skin makes it an ideal organ for in vivo gene transfer. 20 Several gene delivery procedures have been used to investigate cutaneous gene transfer in vivo, including the use of viral and non-viral methods (reviewed in Refs 21 and 22) . Among the novel strategies that hold promise for therapeutic gene therapy applications in the skin is the use of vectors based on the adeno-associated virus (AAV). These vectors are derived from a non-pathogenic and widespread defective parvovirus, and are able to transduce both dividing and non-dividing cells, including skeletal and cardiac muscle, 23, 24 brain 25 and liver. 26, 27 Since recombinant AAV (rAAV) vectors are devoid of any viral genes -which are expressed in trans for the packaging process -they elicit virtually no inflammatory or immune response in the sites of injection. 28, 29 Consequently, transgene expression from these vectors has been shown to last for several months in vivo in a variety of tissues. 30 Besides being able to transduce human keratinocytes in vitro, 31, 32 in the skin in vivo rAAV was observed to transduce hair follicles, sweat gland ducts 33 and the skeletal muscle layer which in rodents is associated with the dermis (panniculus carnosus). 34 In this study we further explore the potential of rAAV gene transfer in the rat skin and describe the effects of the delivery of the 165 aa isoform of VEGF to promote wound repair using these vectors.
Results

Construction and characterization of rAAV vectors
Two vectors based on the adeno-associated virus (AAV) serotype 2 (AAV2) were constructed, expressing the 165 amino acid isoform of human VEGF (AAV-VEGF165) or the LacZ gene (AAV-LacZ) under the control of the human cytomegalovirus (CMV) promoter ( Figure 1a) . For both vectors, high titer (approximately 1 × 10 12 particles/ml) recombinant viral preparations were obtained. Expression of VEGF from AAV-VEGF165 was assessed by transduction of CHO cells followed by immunocytochemistry with anti-VEGF antibodies. As shown in Figure 1b , cells transduced with this vectors showed robust expression of VEGF. The angiogenic potential of transduced VEGF165 was also assessed by the chorion allantoic membrane (CAM) assay. Transduced cells (3 × 10 4 ) were injected on a foamy sponge on top of the chorion membrane of embryonated eggs, and the extent of vascularization was assessed after 3-day incubation. As shown in Figure 1c , in the sample treated with cells transduced with AAV-VEGF165, a large number of vessels was observed radially departing off the sponge, which were not present around the sponge treated with mock-transduced cells. This result is similar to what is commonly observed by adsorbing the sponge with recombinant VEGF, and clearly indicates that the protein produced by the recombinant vector is biologically active.
Transgene expression of rAAV vectors in the rat skin
To determine the location and the time course of rAAV expression in rat skin wounds, full thickness round skin wounds were produced and treated by several intradermal injections of AAV-LacZ or phosphate buffered saline. Animals were killed 10 and 21 days after surgery and skin biopsies of injected wounds and controls were analyzed by X-gal staining. ␤-Galactosidase activity was evident at both time-points in the AAV-LacZ-treated wounds. As shown in Figure 2a , the rAAV-LacZ transduced area was clearly visible on the longitudinal section of the wound biopsy, whereas animals injected with PBS alone showed no specific staining. On histological sections, weak ␤-galactosidase activity was observed in hair follicles (not shown), while high LacZ expression was mostly evident in the panniculus carnosus, a layer of skeletal muscle underlying the dermis (Figure 2b ). In contrast, staining of dermal fibroblasts was rare.
Analogous results were obtained by injecting skin wounds with the AAV vector expressing VEGF165. Immunohistochemistry performed with an antibody reacting with human VEGF at day 21 after injection showed intense reactivity of muscular cells of the panniculus carnosus ( Figure 2c ).
Promotion of neo-angiogenesis and acceleration of wound healing by AAV-VEGF165
To assess the biological effects of AAV-VEGF165 transduction, with particular reference to the induction of neoangiogenesis, the number of blood vessels in the rAAVinjected and mock-injected skin was evaluated by immunohistochemistry using an antibody reacting to ␣-smooth muscle actin (␣-SMA) of vascular smooth muscle cells. Inoculation of AAV-VEGF165 resulted in the increase (approximately three-fold) of ␣-SMA-positive vessels (Figure 3 ), an observation which further corroborates the in vivo angiogenetic potential of VEGF gene transfer. [35] [36] [37] Seventeen Wistar rats were evaluated for the efficacy of AAV-VEGF165 transduction to improve wound healing. In each animal, three full thickness excisional wounds were produced, and treated with between five and seven injections (100 l total) of phosphate buffered saline (mock), AAV-LacZ, or AAV-VEGF165 (1 × 10 12 viral particles/ml each). Lesions were analyzed at different time-points by measuring the wound area. As shown in Figure 4 , the injection of AAV-VEGF165 improved healing of these skin excisional wounds, by both enhancing the sealing of the wound edge to the underlying tissue and accelerating the rate of closure of the wounds from days 6 to 10 after surgery. The reduction of the wound area was statistically significant as compared with AAV-LacZ-injected controls (P Ͻ 0.05) at all time-points. Means and standard errors of means were as follows: treated wounds = 16.37 ± 1 
Histological assessment of skin repair
At histological examination, few differences were observed between control and treated wounds at day 9 from surgery. Control wounds (Figure 5a ) showed moderate to complete re-epithelialization, good epithelial elongation and organization and absence of scab. A moderately thick granulation tissue, rich in fibroblasts and collagen matrix was evident. Few inflammatory cells and slight edema were noted in the deep dermis. As far as angiogenesis is concerned, small capillaries (between two and four per site), as well as vessels of larger diameter were noticed. Such vessels were found in the deep or superficial areas of the wound and were accompanied by
Figure 1 Induction of neo-angiogenesis by AAV-VEGF165. (a) Schematic representation of the two rAAV vectors used in this study
Gene Therapy edema, congestion or erythrorrhages. On the other hand, treated wounds at day 9 (Figure 5d ) clearly demonstrated a complete epithelial remodeling, covering a well-structured and thick granulation tissue. Newly formed capillary vessels (five to six per site) scattered throughout the wound area, as well as congested vessels in the deep dermis and slight edema were apparent. Differences between control and treated wounds were much more evident at day 18 after wounding. In transduced wounds (Figure 5e ), re-epithelialization was com- plete, showing good differentiation, organization and keratinization. A thick and well-structured granulation tissue (Figure 5f ), rich in fibroblasts, oriented parallel to the epithelial surface, abundant collagen bundles in the entire wound area and complete remodeling of the dermis were noted. Numerous newly formed capillary vessels (>10 per site) were frequently observed in the entire wound area. Vessels of greater diameter were disposed vertically toward the epithelial surface of the wound. A slight edema around the small caliber vessels and congestion were occasionally observed in the deep dermal layer. Control wounds at day 18 ( Figure 5b) showed a lower vascular count (four to six per site) and newly formed capillaries were observed in moderate number both in the deep or superficial areas of the wound and in the granulation tissue (Figure 5c ).
In order to provide quantitation to the histological differences observed in AAV-VEGF-transduced wounds as compared with control ones, various parameters were considered, including epidermal and dermal regeneration, granulation tissue thickness, and angiogenesis. Each of these parameters was assessed by at least two independent pathologists who blindly assigned a quantitative score. The criteria utilized for score assessment are 
Figure 4 Efficiency of wound healing after VEGF165 transduction. Shown are means and standard deviations for wound areas either mocktreated or injected with AAV-LacZ or AAV-VEGF165, as indicated. Data are from 17 animals in each of which three full thickness excisional wounds were generated and injected with PBS (mock), AAV-LacZ, or AAV-VEGF165, as indicated. #, statistical significance (P Ͻ 0.05).
reported in Figure 6a . Scores obtained from all the analyzed parameters resulted in clearly increased transduced wounds as compared with controls, and were significantly different at day 18 after wounding ( Figure 6b ).
Discussion
Angiogenesis, together with cell migration, inflammation, provisional matrix synthesis, collagen deposition and re-epithelialization is one of the main features of skin Gene Therapy repair. During wound healing, angiogenic capillary sprouts invade the fibrin-fibronectin-rich wound clot and organize into a microvascular network throughout the granulation tissue. VEGF has been shown to play a pivotal role in the initiation of angiogenesis, based on its ability to induce the expression of proteases and their receptors, important for the cellular invasion of the extracellular matrix, to promote endothelial cells proliferation, and to prevent their apoptosis. 38 Elevated VEGF mRNA levels were found in keratinocytes at the wound edges and in keratinocytes that migrate to cover the wound surface. 10 Occasional mononuclear cells, probably macrophages, in the wound bed also express VEGF. Moreover, antibody neutralization of this cytokine was demonstrated to inhibit formation of wound granulation tissue. 39 From the above considerations, it follows that local treatment of wounds with VEGF protein or through VEGF gene transfer might represent an important tool to promote efficient wound repair, especially in conditions in which the physiological healing process is impaired, such as in diabetes. 40 As far as treatment with the VEGF protein is concerned, animal experiments and clinical trials have indicated that large, often repeated doses of growth factor are required to attain clinical benefit, suggesting that exogenous presentation can lead to clearance, sequestration 41 or destruction 42 of the factor. In contrast, gene transfer might overcome the shortcomings of direct application of the growth factor and promote sustained production and release of the growth factor within the wound site.
Among the vectors which can be considered for thera-
Figure 5 Histological examination of AAV-VEGF-165-and AAV-LacZ-transduced wounds. (a) Photomicrograph of AAV-LacZ-treated wound at day 9. The picture shows good epithelial and granulation tissue organization, with few capillaries in the superficial and deep dermis (hematoxylin/eosin; original magnification ×50). (b and c) Photomicrographs of AAV-LacZ-treated wound at day 18. A dense and well-structured granular tissue is evident, with few newly formed capillary vessels. Panel c shows detail of the granulation tissue (original magnification ×50). (d) Photomicrograph of AAV-VEGF165-treated wound at day 9. The picture shows intense epidermis and dermis remodeling, with numerous small vessels scattered throughout the wound area (hematoxylin/eosin; original magnification ×50). (e and f) Photomicrographs of AAV-VEGF165-treated wound at day 18. The picture shows complete remodeling of epithelium and dermis. Dense proliferation of newly formed capillaries, as well as vessels of greater diameter is observed, distributed in the entire wound area. Panel f shows a detail of the granulation tissue, displaying dense proliferation of fine and slightly congested small vessels (hematoxylin/eosin; original magnification ×50).
peutic application to the skin, those based on AAV appear to possess several appealing features, including the capacity to promote long-term expression of the therapeutic gene in the absence of signs of inflammation or immune response. Using LacZ gene marker studies, we found that AAV transduction is highly efficient in the muscular tissue of the panniculus carnosus of rodents, again reinforcing the notion of the exquisite tropism of these vectors for muscular cells. 43 Transduction of this tissue results in prolonged expression of the marker transgene and causes no apparent histological or functional change in the wound repair process.
Similar to LacZ, the injection of a rAAV encoding the 165 amino acid isoform of VEGF also resulted in prolonged expression of this cytokine, with the functional consequence of greatly increasing the formation of new blood vessels in the wounded tissue. Expression of VEGF165 significantly enhanced wound repair, an event which correlated well with improvement of all the histological parameters which were considered, including epidermal and dermal regeneration, thickness of granulation tissue, and formation of well-structured capillary vessels.
Taken altogether, on one hand these results further emphasize the relevance of the angiogenetic process in wound repair and the potent role that VEGF has in triggering new blood vessel formation. On the other hand, they also indicate the feasibility of a gene therapy approach for wound healing aimed at potentiating or restoring angiogenesis. This approach might be of particular relevance in all clinical situations of impaired vascularization, including normal aging, decubitus, diabetes, or therapeutic intervention. 44, 45 Finally, in light of the prolonged gene expression which can be obtained in the rodent skin using rAAV vectors, this delivery system should also be considered as a novel and powerful tool to assess the biological consequences of long-term overexpression
Figure 6 6 Histological scores of wound healing after AAV-VEGF-165-or AAV-LacZ transduction. (a) Criteria to evaluate histological scores of wound healing. (b) Assessment of wound healing at 9 and 18 days after wounding and treatment with AAV-VEGF165 or AAV-LacZ, as indicated, according to the histological scores of panel a. #, statistical significance (P Ͻ 0.05).
of other growth factors or growth factor combinations, which might be relevant to wound healing or to other physiological or pathological processes in the skin.
Materials and methods rAAV vector preparation and characterization
Two recombinant AAV vectors were obtained in this study, expressing the LacZ reporter gene and the cDNA for the 165 amino-acid isoform of VEGF (VEGF165) under the control of the strong and constitutive cytomegalovirus (CMV) immediate-early promoter. Both constructs were based on plasmid pUF-5, kindly provided by N Muzyczka (University of Florida, Gainesville, FL, USA). Infectious vector stocks were generated in 293 cells, cultured in 150 mm diameter Petri dishes, by co-transfecting each plate with 15 g of each vector plasmid, together with 45 g of the packaging/helper plasmid, pDG (kindly provided by JA Kleinschmidt, DKFZ, Heidelberg, Germany), expressing AAV and adenovirus helper functions. 47 Twelve hours after transfection, the medium was replaced by fresh medium and 3 days later the medium was collected and the cells harvested by scraping. After three freeze-thaw cycles in dry ice/ethanol bath and Gene Therapy 37°C water bath, cell lysates were fractionated using ammonium sulfate precipitation. rAAV particles were then purified by CsCl gradient centrifugation in a SW41Ti rotor at 288 000 g for 36 h. Twelve to 16 fractions of 10 drops each were collected by inserting a G-21 needle below the rAAV band and their refractive index was determined. The six fractions with index closest to 1.3715 (corresponding to a density of 1.40 g/cm 3 ) were dialyzed against phosphate buffered saline (PBS) at 4°C overnight and stored at Ϫ80°C. 48 rAAV titers were determined by measuring the copy number of viral genomes in pooled, dialyzed gradient fractions. This was achieved by a competitive PCR procedure, 49 using primers and competitors mapping in the CMV promoter region common to all vectors. 50 The purified viral preparations used for this work had particles titers of approximately 1 × 10 12 viral genomes per ml.
Cell transduction and angiogenic assay
For in vitro cell transduction, 1.5 × 10 5 CHO cells were seeded on Lab-Tek II Chamber Slide System (Nalge; Nunc, IL, USA) and treated overnight with 1 mM hydroxyurea. After replacement of the medium, recombinant AAV-VEGF165 (1 × 10 8 particles) was added and cells were incubated for 24 h at 37°C. Cells were then washed with PBS and fixed for 10 min in methanol at Ϫ20°C. After this step, cells were rehydrated in graded ethanols and processed as described below for immunohistochemistry.
To perform chorion allantoic membrane (CAM) angiogenic assay, fertilized White Leghorn chicken eggs were incubated under conditions of constant humidity at 37°C. After 3 days incubation, 2-3 ml of albumen were removed to detach the developing CAM from the shell and a square window was produced on the shell. The window was covered with a glass of the same dimension, sealed with paraffin and the eggs were returned to the incubator. On day 8 of incubation, a sterilized gelatin sponge (1 mm 3 ) (Gelfoam; Upjohn, Kalamazoo, MI, USA) was placed on the growing CAM under sterile conditions. When the sponge was adherent to the CAM, 5 l of AAV-VEGF165-transduced CHO cell suspension (6 × 10 6 cells/ml) were pipetted on to the sponges. Sponges containing untransduced CHO cells were used as negative controls. After 4 days, CAMs were examined and photographed in ovo under a stereomicroscope.
Animals and experimental protocol
All animal procedures were in accordance with the Declaration of Helsinki and with the Guide for the Care and Use of Laboratory Animals.
Adult male Wistar rats weighing 250 to 300 g each were used in the study. During the experiments, animals were housed one per cage, maintained under controlled environmental conditions (12 h light/dark cycle, temperature approximately 23°C). After general anesthesia with ketamine hydrochloride (50 mg/kg), the hair on the back was shaved and the skin washed with sterile water. Three full-thickness round skin wounds (8 mm diameter) were produced on the dorsum of each rat with a standard biopsy punch and left undressed. After surgery, the right wound of each rat was treated with rAAV-VEGF165 (treated wounds), while the left wounds were administered with rAAV-LacZ (control wounds) or PBS. The viral suspensions were injected intradermally around the wound using 1 cc syringe and 30 gauge needle; five to seven injections of approximately 20 l each (corresponding to approximately 10 11 vector particles) per wound were administered. Injections were spaced about 3-4 mm. The treated and control wound areas were inspected and evaluated at days 6, 8 and 10 following surgery. Animals were killed at days 9 and 18, and wounds were harvested and fixed overnight in 10% buffered formalin for histological evaluation. The other two groups of animals were killed at days 10 and 21 for the evaluation of ␤-galactosidase activity and immunohistochemical analysis.
Histological evaluation
Samples for histological evaluation were processed immediately after removal. Perpendicular sections to the anterior-posterior axis of the wound were fixed in 10% buffered formalin, dehydrated with graded ethanols and embedded in paraffin. Five-m thick sections were stained with hematoxylin and eosin, periodic acid-Schiff (PAS), and Weigert-van Gieson stains. As part of the morphologic examination, six slides of each biopsy (in particular, two hematoxylin and eosin-stained sections, two periodic acid Schiff-stained sections, and two Weigert-van Gieson-stained sections) were examined by two independent pathologists without knowledge of the previous treatment, who used masked slides under the microscope from 20× to 100× magnification. The following parameters were evaluated: re-epithelialization, granulation tissue formation and angiogenesis. The histological score adopted in this study was evaluated according to literature data regarding wound healing in experimental models. 16 Immunohistochemistry Wounds collected at days 10 and 21 were fixed in 2% formaldehyde, embedded in paraffin, sectioned at 5 m thickness and mounted on to slides. Rehydrated serial paraffin sections were immersed in Tissue Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) to reactivate hidden or masked epitopes and then placed in a microwave for 7 min at 350 W. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 5 min. Samples were then rinsed in PBS and blocked with non-immune horse serum followed by incubation with a polyclonal rabbit anti-human VEGF antibody (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or mouse monoclonal anti-␣ smooth muscle actin antibody (1:330) (Sigma, St Louis, MO, USA). Slides were washed with PBS and then incubated with biotinylated horse secondary antibody (Vector Laboratories). After washing with PBS an avidin-biotin complex (Vector Laboratories) was added, slides were rinsed again in PBS and developed with chromagen 3,3'-diaminobenzidine (Lab Vision, CA, USA).
Detection of ␤-galactosidase activity Wounds collected at days 10 and 21 were briefly washed in cold PBS additioned with 0.02% NP40, fixed in 2% buffered paraformaldehyde and 0.02% NP40 for 45 min at room temperature, washed again in PBS and immersed in a solution containing 1 mg/ml X-gal, 2 mM MgCl 2 , 5 mM K3Fe(Cn) 6 , 5 mM K4Fe(Cn) 6 , 0.02% NP40 in PBS at 37°C overnight. Tissue samples were then rinsed in PBS, fixed in 4% formaldehyde, embedded in paraffin, cut into 5 m thick sections, mounted on to slides and counterstained with nuclear fast red.
Statistical analysis
Statistical analysis was performed by the Student's t test on paired samples using the StatView 4.5 statistical software package for the Macintosh (Abacus Concepts, Berkeley, CA, USA).
